troke is a leading cause of death and disability in industrialized countries and of the 2 major types of stroke, cerebral infarction predominates, although hemorrhagic stroke remains common in Asian populations. 1 Risk factors for cerebral infarction have not been well clarified, except for hypertension (HT). 2 Findings regarding the relation between serum total cholesterol (TC) or low-density lipoprotein-cholesterol (LDL-C) and cerebral infarction are inconsistent in observational studies, 3-16 whereas cholesterol-lowering trials have shown a decrease in the risk of cerebral infarction among patients assigned to statin treatment. 17, 18 The role of serum high-density lipoprotein-choCirculation Journal Vol.69, January 2005 lesterol (HDL-C) is receiving particular interest in the epidemiology of cerebral infarction. Low concentrations of serum HDL-C have been fairly consistently associated with an increased risk of cerebral infarction. [4] [5] [6] [7] [8] [9] 14, 19 Several, 5, 7, 8, 12, 15, 19 but not all, 3, 6 prospective studies reported that diabetes mellitus (DM) was associated with an increased risk of cerebral infarction. In the study reported here, we examined the relation of serum TC and HDL-C and other factors to the risk of cerebral infarction using data from the Kyushu Lipid Intervention Study (KLIS), a primary prevention trial of coronary heart disease (CHD) events and cerebral infarction in Japanese men with moderately elevated concentrations of serum TC. [20] [21] [22] [23] Furthermore, because few studies have investigated the risk factors for cerebral infarction in elderly persons, 6, 15, 19 we examined the association with these factors in middle-aged and elderly men separately.
All the patients gave consent to participate in the study. Ineligible for the study were a history of myocardial infarction, coronary bypass surgery, coronary angioplasty, cerebral hemorrhage, or cerebral infarction; serum HDL-C concentration of 80 mg/dl or greater; and a life-limiting morbid condition such as severe renal or hepatic disease. Each physician was instructed to randomly allocate patients to either pravastatin treatment or conventional treatment as specified in a sealed envelope, but participating physicians did not necessarily follow that instruction. 20 The patients were followed up until the end of 1997 for the occurrence of coronary events and cerebral infarction. The study was approved by the ethical committee of the principal investigator's affiliated institution.
Subjects
The present analysis included 4,349 of the 5,640 enrolled men; 1,291 were excluded for the following reasons: (1) withdrawal of consent (n=147), (2) no institutional contract (n=616; this category represented the lack of a written agreement between a participating hospital or clinic and a sponsoring pharmaceutical company, which became necessary in the course of the study because of the introduction of a new regulation for clinical trials in Japan), (3) found to be ineligible during follow-up (n=97), and (4) missing data (n=431).
Laboratory and Clinical Data
Serum concentrations of TC, HDL-C, triglycerides (TG), and other clinical and biochemical variables were determined at baseline and subsequently in the follow-up. Laboratory measurements were done at different laboratories, but each physician was requested to use the same laboratory throughout the study period. Average serum TC concentrations during the follow-up were determined on the basis of periodical follow-up measurements at 3 months, 6 months, and every year thereafter; the number of measurements ranged from 1 to 10 with a median of 6. Serum LDL-C was not used in the present study because the Friedewald method 24 was not applicable for 7% of the men who even at baseline had serum TG concentrations of 400 mg/dl or greater (n=282) or who had missing data (n=5). HDL-C was not measured in 46 men during the follow-up.
Hypertension was defined as present if a patient had systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥95 mmHg or if was under medication for HT.
Subjects were defined as having DM if they had either fasting plasma glucose ≥140 mg/dl or hemoglobin A1c ≥6.5% or if they were under medication for DM. The presence of angina pectoris (AP) and prior use of hypolipidemic drugs were based on the report of the study physicians. Statin use was defined if any statin drugs were prescribed during the follow-up period. Height and body weight were recorded, and body mass index (kg/m 2 ) was calculated as an index of obesity. Current habits of smoking and alcohol drinking were ascertained, together with the number of cigarettes smoked per day and frequency of alcohol drinking per week.
Endpoints
Cerebral infarction was the secondary endpoint and coronary events were the primary endpoint. Definite cerebral infarction was diagnosed when typical symptoms and signs were accompanied with diagnostic findings on brain imaging or cerebral angiography. Diagnosis based only on clinical signs and symptoms was regarded as a suspected case. 20 These endpoints were determined by the Endpoint and Adverse Effect Committee on the basis of periodical reports from the study physicians and, if necessary, by supplementary inquiry. From January to May 1998, an ad hoc survey was carried out to ascertain the occurrence of coronary events and cerebral infarction up to the end of 1997. Vital status was unknown for 36 men, and cerebral infarction and coronary events were not ascertained for 97 men. A total of 81 definite cases and 10 suspected cases of cerebral infarction were identified in an average observation period of 5.05 years. One definite case and 2 suspected cases of cerebral infarction occurred subsequent to a coronary event. None developed coronary events after cerebral infarction. Only definite cases of cerebral infarction were used in the present study, and the follow-up period continued until the event of a definite cerebral infarction regardless of coronary events.
Statistical Analysis
The Cox proportional hazards model was used to examine the relation of clinical and behavioral factors to the risk of cerebral infarction. The principal model included indicator variables for age (5-year class), baseline serum TC (<240, 240-259, ≥260 mg/dl), follow-up TC (<220, 220-239, ≥240 mg/dl), serum HDL-C (<40, 40-59, ≥ 60 mg/dl), BMI (<22.5, 22.5-24.9, ≥25.0 kg/m 2 ), AP, HT, DM, prior use of lipid-lowering drugs, current smoking (0, 1-19, ≥20 cigarettes per day), and alcohol use (0, 1-4, ≥5 days per week). The association with statin use was examined using the model with and without follow-up TC. Adjusted relative risk and 95% confidence intervals (CI) were obtained from a regression coefficient and standard error for the corresponding indicator variable. Statistical significance of the interaction was assessed by the likelihood ratio test. Statistical significance was declared when the 95%CI did not include unity or when the two-sided p-value was less than 0.05. Statistical computations were done with the SAS software version 8.2 (SAS Institute, Inc, Carry, NC, USA).
Results
The mean age of the study subjects was 58.0 years, and the mean concentrations of baseline and follow-up serum TC were 253 mg/dl and 221 mg/dl, respectively. The characteristics of the study subjects are summarized by statin use in Table 1 . Serum TC concentrations were higher at baseline and lower during the follow-up among men taking statins than in those not taking the medication. The differences were highly significant. The number of cerebral infarctions was 47 (1.7%) in men taking statins and 34 (2.1%) in those who were not.
Although baseline TC was not associated with the risk of cerebral infarction, the follow-up TC concentration was strongly, positively associated with cerebral infarction (Table 2) . A nearly 4-fold increase in the risk was observed for men with a follow-up serum TC ≥240 mg/dl compared with those with a concentration <220 mg/dl. High concentrations of serum HDL-C (≥60 mg/dl) was associated with a lower risk of cerebral infarction, although the decrease was not statistically significant (p=0.08). Diabetes mellitus was associated with a statistically significant increase in the risk of cerebral infarction. Men with AP or HT also showed a moderate increase in the risk, and the increased risk associated with HT was statistically significant. No clear association was observed for BMI. A statistically nonsignificant decrease in the risk was observed for each of the intermediate categories of smoking and alcohol use.
Statin use was associated with a statistically non-significant, moderate decrease in the risk of cerebral infarction without adjustment for follow-up TC; adjusted relative risk for statin use was 0.73 (95%CI 0.46-1.16) when follow-up TC was replaced with statin use in the model used for Table 2 . When both statin use and follow-up TC were included in the model, the adjusted relative risk for statin use was 0.91 (95%CI 0.57-1.47), and adjusted relative risks for the follow-up TC concentrations of <220, 220-239, and ≥240 mg/dl were 1.00 (referent), 1.69 (95%CI 0.97-2.97), and 3.76 (95%CI 2.15-6.56), respectively. Further, the association between follow-up TC and cerebral infarction was examined by statin use. In that analysis, follow-up TC was used as continuous variable to avoid unstable estimation because of the smaller number of cases. Adjusted relative risks for an increase of 10 mg/dl in TC were 1.31 (95%CI 1.14-1.51) in non-statin users and 1.11 (95%CI 0.99-1.25) in statin users. The increased risk associated with follow-up TC seemed to be attenuated in the latter group, but the interaction was not statistically significant (p=0.16).
When separate analyses were done for men aged less than 65 years and those aged 65 years or older (Table 3) , the increased risk of cerebral infarction associated with elevated concentrations of serum TC during the follow-up was slightly more evident in the elderly men than in the middle-aged men. A decreased risk associated with high concentrations of HDL-C was more apparent in the middleaged men, but neither of the decreases in risk for the 2 age groups was statistically significant. Diabetes mellitus and AP were each associated with a statistically significant increase in the risk of cerebral infarction in the elderly only. Hypertension was statistically non-significantly associated with an increased risk in both middle-aged and elderly men. As regards alcohol use, a statistically significant decrease in the risk was observed for the category of 1-4 days per week in elderly men only.
Discussion
Methodological problems need to be clarified before interpreting the present findings. Because the patients were non-randomly allocated to pravastatin treatment, cardiovascular risk factors were generally more prevalent among statin users, as shown in Table 1 . Although statistical adjustment was done for these factors, residual confounding effects possibly remained. Statin use was strongly associated with lower concentrations of follow-up TC, and it may be difficult to conclude which is more importantly related to the risk of cerebral infarction on statistical grounds. All the patients were treated for hypercholesterolemia regard- less of statin use, and cardiovascular risk factors ascertained at baseline may have changed in varying degrees. The relation of clinical risk factors at baseline to the risk of cerebral infarction may have been attenuated because comorbid conditions such as HT and DM were probably well treated during the follow-up. 25 Finally, results from the subgroup analysis should be interpreted cautiously. In the analysis by statin use or by age group, the estimated relative risks were more subject to random fluctuation because of the smaller number of cases. The present study demonstrated an evident, positive association between the serum TC concentration in the follow-up period, but not at baseline, and cerebral infarction. Statin use was associated with a moderate, statistically nonsignificant decrease in the risk of cerebral infarction when follow-up TC was not taken into consideration. The magnitude of the decrease in the risk associated with statin use was the same as reported for pravastatin use previously in the KLIS. 21 However, the decreased risk associated with statin use was almost nullified after adjustment for follow-up TC. The positive association with follow-up TC remained after adjustment for statin use. These findings indicate that lowering cholesterol itself is important in the prevention of cerebral infarction among men with moderate hypercholesterolemia.
It remains a matter of controversy whether the reduced risk of stroke or ischemic stroke associated with use of statins can be ascribed to the cholesterol-lowering effect of statins or to other properties. 26, 27 Statins are known to ameliorate endothelial dysfunction, stabilize atherosclerotic plaques, and modify inflammatory responses and thrombus formation. 28 The observation that statin treatment confers a reduced risk of ischemic stroke among hypertensive patients with average or below-average cholesterol concentrations suggests a role of the nonlipid-lowering effects of statins. 29 On the other hand, a meta-analysis of randomized controlled trials indicated that the beneficial effect on stroke incidence was seen only when the final cholesterol concentration was <232 mg/dl (6.0 mmol/L), suggesting the importance of lowering cholesterol. 30 Another meta-analysis of 7 prospective observational studies showed a statistically significant decrease of 15% in the risk of thromboembolic stroke for a 1.0 mmol/L decrease in LDL-C. 31 In this regard, the interaction between statin use and follow-up TC is of particular interest. In the present study, the positive relation between follow-up TC and cerebral infarction seemed weaker among statin users. The findings may be interpreted as suggestive of a protective effect of statins other than their cholesterol-lowering effect, but it is also possible that uncontrolled risk factors other than elevated concentrations of serum TC may be major determinants of the risk of cerebral infarction among statin users because they are generally at a higher risk of cardiovascular diseases on entry. A larger study is needed to clarify the relation between achieved concentrations of TC or LDL-C and cerebral infarction among patients under treatment with different classes of cholesterol-lowering drugs.
The positive association between serum TC in the follow-up and cerebral infarction seemed to be stronger in the elderly men than in the middle-aged men in the present study. Not many studies have addressed the relation between cholesterol and cerebral infarction in the elderly. In a prospective study of those aged 60 years or older, 6 serum TC was unrelated to the risk of cerebral infarction. In a clinical trial of the elderly in Europe, 32 statin use did not result in a decrease in the incidence of stroke, not specifically of cerebral infarction, but there was a substantial decrease in coronary events. On the other hand, in Japanese men in Hawaii, 15 a statistically significant increase in the risk of ischemic stroke was observed for the highest vs lowest quartile of serum TC in men aged 60-74 years, but not in those aged 51-59 years. The seemingly differential association with serum TC according to age group in the present study could be a random fluctuation as discussed earlier, but the findings are consistent with the progression of atherosclerosis; that is, atherosclerosis in the cerebral arteries occurs later in life than coronary atherosclerosis. 15 Although HDL-C has been emphasized as a predictor of coronary heart disease in Western countries 33 and in Japan, 34 it is only very recently that low concentrations of serum HDL-C were found to be associated with an increased risk of cerebral infarction. [4] [5] [6] [7] [8] [9] 14, 19 Our findings on HDL-C add to evidence for a protective association between HDL-C and cerebral infarction. The non-HDL-C concentration may be more useful than that of TC in predicting the risk of cardiovascular diseases. 35 When the non-HDL-C concentrations at base line and during the follow-up, categorized at each quartile, were included in the model used for Table 2 instead of the baseline and follow-up TC concentrations and HDL-C at baseline, the relation between non-HDL-C concentration during the follow-up and the risk of cerebral infarction was not as strong as observed for follow-up TC; adjusted relative risk for the highest (≥188 mg/dl) vs lowest (<153 mg/dl) quartile was 3.16 (95%CI 1.62-6.16). The role of serum TG in the development of atherosclerotic diseases is also of recent interest because of its relevance to metabolic syndrome. 33, 35 In the present study, however, the baseline concentrations of serum TG were unrelated to the risk of cerebral infarction; when serum TG were additionally included in the model used for Table 2 , adjusted relative risks for triglycerides <150, 150-199, and ≥200 mg/dl were 1.00 (referent), 1.17 (95%CI 0.68-2.04), and 0.95 (95%CI 0.56-1.63), respectively.
Diabetes mellitus, HT and AP were found to be related to an increased risk of cerebral infarction, especially among the elderly men. Further confirmation is needed regarding possible differential relations according to age group. The present findings regarding smoking and alcohol use were difficult to interpret because past smokers and past drinkers were not distinguished from lifelong nonsmokers and nondrinkers. Occasional alcohol use was related to a substantial decrease in the risk of cerebral infarction among elderly men. In general, no material association between alcohol use and cerebral infarction has been found in prospective studies. 3, 7, [10] [11] [12] Exceptionally, alcohol use was associated with a decreased risk of atherosclerotic stroke in a study of elderly persons. 19 Further studies are warranted in view of much evidence that moderate alcohol consumption confers protection against atherosclerosis. 36, 37 In summary, in men undergoing treatment for moderately elevated concentrations of serum TC, higher concentrations during the treatment, but not at baseline, were strongly related to an increased risk of cerebral infarction and the decreased risk associated with statin use was almost nullified when follow-up TC was taken into account. Lowering cholesterol itself, rather than the choice of cholesterollowering regimen, is important in the prevention of cerebral infarction in patients with hypercholesterolemia.
